‘According to the U.S. Government Accountability Office’s May 2025 report on the state of organ-on-a-chip technology, New Approach Methods (or NAMs) are playing an increasingly important role in drug development, but they lack established benchmarks,’ writes an L.A. Times reader.
To the editor: While only a small percentage of ALS cases are associated with the SOD1 gene mutation, the SOD1 mouse model actively contributed to the development of two key FDA-approved ALS drugs, riluzole and edaravone. More recently, scientists di… [1846 chars]
Source: Los Angeles Times | Published: 2026-02-04T14:30:00Z
Credit: Los Angeles Times
